LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS CANbridge to Hold Investor CallBEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development...

Faraday Future has debuted the first All-Ability aiHypercar, the FF 91 2.0 Futurist Alliance, which has undergone a comprehensive upgrade and iteration in its technological architecture since the FF 91 introduction six years ago. Faraday Future announced the AI-Powered “6x4...

Production guidance from Hess Corporation for the Stabroek Block indicates a reduction in 2023 Q2 compared to the prior quarter, as Exxon moves to execute maintenance on the Liza Phase 2 project.  Net production for Hess, a 30% stakeholder in...

SAR’579/IPH6101, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was well tolerated and induced 3...

The latest crash-test achievement joins the announcements made late last year of the FF91’s EPA rating of 381 miles of EV range and the official CARB certification received as a zero-emissions vehicle. The first phase of the Company’s three-phase delivery...

Treatment of all Phase Ia cohorts in monotherapy completed with no safety concerns Stabilization of injected lesions in 11/18 patients An independent Safety Review Committee has approved initiation of the combination trial with pembrolizumabSTRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Euronext...

After a Single Administration of JK07, Patients in All Dose Cohorts Showed Improvement in Ejection Fraction (EF) Through Day 90 JK07 was Generally Safe and Well-Tolerated JK07 is a First-in-class Antibody Fusion and Selective ErbB4 Agonist Company Plans to Initiate Phase 2...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting...

Development drilling continues at ExxonMobil Guyana’s Liza site in the Stabroek Block with the Noble Tom Madden drillship.  Guyana’s Maritime Administration (MARAD) said activities commenced on May 6 and will end on June 30 with 29 additional support vessels.  The well...

Guyana’s Liza Destiny and Liza Unity floating production, storage and offloading (FPSO) vessels have allowed the country to earn a whopping US$2.2 billion in royalties and profit oil in a three-year period spanning from March 11, 2020 to March...